ADMA Biologics Inc (ADMA) is now in the Undervalued zone, suggesting that its current forward PS ratio of 7.07 is considered Undervalued compared with the five-year average of 1.01. The fair price of ADMA Biologics Inc (ADMA) is between 31.46 to 41.40 according to relative valuation method. Compared to the current price of 16.58 USD , ADMA Biologics Inc By Undervalued By 47.29%.

Relative Value

Fair Zone

31.46-41.40

Current Price：16.58

47.29%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is ADMA Biologics Inc (ADMA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

ADMA Biologics Inc (ADMA) has a current Price-to-Book (P/B) ratio of 9.88. Compared to its 3-year average P/B ratio of 11.06, the current P/B ratio is approximately -10.67% higher. Relative to its 5-year average P/B ratio of 7.75, the current P/B ratio is about 27.55% higher. ADMA Biologics Inc (ADMA) has a Forward Free Cash Flow (FCF) yield of approximately 0.96%. Compared to its 3-year average FCF yield of -0.78%, the current FCF yield is approximately -223.46% lower. Relative to its 5-year average FCF yield of -17.23%, the current FCF yield is about -105.55% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for ADMA competitors is 51.66, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA.O) exhibits a P/S ratio of 7.07, which is -86.31% above the industry average. Given its robust revenue growth of 18.39%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of ADMA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of ADMA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is ADMA currently overvalued or undervalued?

What is ADMA Biologics Inc (ADMA) fair value?

ADMA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of ADMA Biologics Inc (ADMA) is between 31.46 to 41.40 according to relative valuation method.

How does ADMA's valuation metrics compare to the industry average?

The average P/S ratio for ADMA's competitors is 51.66, providing a benchmark for relative valuation. ADMA Biologics Inc Corp (ADMA) exhibits a P/S ratio of 7.07, which is -86.31% above the industry average. Given its robust revenue growth of 18.39%, this premium appears unsustainable.

What is the current P/B ratio for ADMA Biologics Inc (ADMA) as of Mar 03 2026?

As of Mar 03 2026, ADMA Biologics Inc (ADMA) has a P/B ratio of 9.88. This indicates that the market values ADMA at 9.88 times its book value.

What is the current FCF Yield for ADMA Biologics Inc (ADMA) as of Mar 03 2026?

As of Mar 03 2026, ADMA Biologics Inc (ADMA) has a FCF Yield of 0.96%. This means that for every dollar of ADMA Biologics Inc's market capitalization, the company generates 0.96 cents in free cash flow.

What is the current Forward P/E ratio for ADMA Biologics Inc (ADMA) as of Mar 03 2026?

As of Mar 03 2026, ADMA Biologics Inc (ADMA) has a Forward P/E ratio of 21.80. This means the market is willing to pay $21.80 for every dollar of ADMA Biologics Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for ADMA Biologics Inc (ADMA) as of Mar 03 2026?

As of Mar 03 2026, ADMA Biologics Inc (ADMA) has a Forward P/S ratio of 7.07. This means the market is valuing ADMA at $7.07 for every dollar of expected revenue over the next 12 months.

ADMA Valuation